{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:16:28Z","timestamp":1787062588968,"version":"build-2736575974"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.jpba.2021.114356","type":"journal-article","created":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T22:11:05Z","timestamp":1630534265000},"page":"114356","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":80,"special_numbering":"C","title":["The development and validation of a novel LC-MS\/MS method for the simultaneous quantification of Molnupiravir and its metabolite \u00df-d-N4-hydroxycytidine in human plasma and saliva"],"prefix":"10.1016","volume":"206","author":[{"given":"Alieu","family":"Amara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujan Dilly","family":"Penchala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Else","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Hale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"FitzGerald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3827-4387","authenticated-orcid":false,"given":"Lauren","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Lyons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2769-0967","authenticated-orcid":false,"given":"Saye","family":"Khoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.jpba.2021.114356_bib1","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01348-19","article-title":"Small-molecule antiviral \u03b2-d-N (4)-hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance","volume":"93","author":"Agostini","year":"2019","journal-title":"J. Virol."},{"issue":"10259","key":"10.1016\/j.jpba.2021.114356_bib2","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(20)32013-4","article-title":"Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"396","author":"Group","year":"2020","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.jpba.2021.114356_bib3","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1093\/ofid\/ofaa241","article-title":"Antiviral activity and safety of darunavir\/cobicistat for the treatment of COVID-19","volume":"7","author":"Chen","year":"2020","journal-title":"Open Forum Infect. Dis."},{"issue":"19","key":"10.1016\/j.jpba.2021.114356_bib4","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19 \u2013 final report","volume":"383","author":"Beigel","year":"2020","journal-title":"New Engl. J. Med."},{"issue":"7","key":"10.1016\/j.jpba.2021.114356_bib5","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1473-3099(14)70717-0","article-title":"Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b\/3 trial","volume":"14","author":"Haffizulla","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.jpba.2021.114356_bib6","doi-asserted-by":"crossref","unstructured":"B. Boras, R.M. Jones, B.J. Anson, D. Arenson, L. Aschenbrenner, M.A. Bakowski, N. Beutler, J. Binder, E. Chen, H. Eng, H. Hammond, J. Hammond, R.E. Haupt, R. Hoffman, E.P. Kadar, R. Kania, E. Kimoto, M.G. Kirkpatrick, L. Lanyon, E.K. Lendy, J.R. Lillis, J. Logue, S.A. Luthra, C. Ma, S.W. Mason, M.E. McGrath, S. Noell, R.S. Obach, M.N. O\u2032Brien, R. O\u2032Connor, K. Ogilvie, D. Owen, M. Pettersson, M.R. Reese, T.F. Rogers, M.I. Rossulek, J.G. Sathish, N. Shirai, C. Steppan, M. Ticehurst, L.W. Updyke, S. Weston, Y. Zhu, J. Wang, A.K. Chatterjee, A.D. Mesecar, M.B. Frieman, A.S. Anderson, C. Allerton, Discovery of a Novel Inhibitor of Coronavirus 3CL Protease for the Potential Treatment of COVID-19, bioRxiv (2021) 2020.09.12.293498.","DOI":"10.1101\/2020.09.12.293498"},{"issue":"515","key":"10.1016\/j.jpba.2021.114356_bib7","doi-asserted-by":"crossref","first-page":"eaax5866","DOI":"10.1126\/scitranslmed.aax5866","article-title":"Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia","volume":"11","author":"Toots","year":"2019","journal-title":"Sci. Transl. Med"},{"issue":"541","key":"10.1016\/j.jpba.2021.114356_bib8","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb5883","article-title":"An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice","volume":"12","author":"Sheahan","year":"2020","journal-title":"Sci. Transl. Med"},{"key":"10.1016\/j.jpba.2021.114356_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2019.104597","article-title":"The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal venezuelan equine encephalitis virus infection","volume":"171","author":"Painter","year":"2019","journal-title":"Antivir. Res"},{"key":"10.1016\/j.jpba.2021.114356_bib10","doi-asserted-by":"crossref","unstructured":"W.P. Painter, W. Holman, J.A. Bush, F. Almazedi, H. Malik, N.C.J.E. Eraut, M.J. Morin, L.J. Szewczyk, G.R. Painter, Human Safety, Tolerability, and Pharmacokinetics of a Novel Broad-Spectrum Oral Antiviral Compound, Molnupiravir, with Activity Against SARS-CoV-2, medRxiv (2020) 2020.12.10.20235747.","DOI":"10.1101\/2020.12.10.20235747"},{"key":"10.1016\/j.jpba.2021.114356_bib11","doi-asserted-by":"crossref","unstructured":"K. Rosenke, F. Hansen, B. Schwarz, F. Feldmann, E. Haddock, R. Rosenke, K. Meade-White, A. Okumura, S. Leventhal, D.W. Hawman, E. Ricotta, C.M. Bosio, G. Saturday, H. Feldmann, M.A. Jarvis, Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model, Res Sq (2020) rs.3.rs-86289.","DOI":"10.21203\/rs.3.rs-86289\/v1"},{"key":"10.1016\/j.jpba.2021.114356_bib12","unstructured":"F.a.D.A. US Department of Health and Human Services, Center for Drug Evaluation and Research (CDER), Center for Veterinary medicine (CVM). Bioanalytical Method Validation, Guidance for Industry, 2020."},{"issue":"29","key":"10.1016\/j.jpba.2021.114356_bib13","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1016\/j.jchromb.2009.09.014","article-title":"Simultaneous measurement of cortisol and cortisone in human saliva using liquid chromatography-tandem mass spectrometry: application in basal and stimulated conditions","volume":"877","author":"Perogamvros","year":"2009","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"issue":"3","key":"10.1016\/j.jpba.2021.114356_bib14","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/0004563217724178","article-title":"20alpha- and 20beta-dihydrocortisone may interfere in LC-MS\/MS determination of cortisol in saliva and urine","volume":"55","author":"Israelsson","year":"2018","journal-title":"Ann. Clin. Biochem"},{"key":"10.1016\/j.jpba.2021.114356_bib15","doi-asserted-by":"crossref","unstructured":"S.H. Khoo, R. FitzGerald, T. Fletcher, S. Ewings, T. Jaki, R. Lyon, N. Downs, L. Walker, O. Tansley-Hancock, W. Greenhalf, C. Woods, H. Reynolds, E. Marwood, P. Mozgunov, E. Adams, K. Bullock, W. Holman, M.D. Bula, J.L. Gibney, G. Saunders, A. Corkhill, C. Hale, K. Thorne, J. Chiong, S. Condie, H. Pertinez, W. Painter, E. Wrixon, L. Johnson, S. Yeats, K. Mallard, M. Radford, K. Fines, V. Shaw, A. Owen, D.G. Lalloo, M. Jacobs, G. Griffiths, Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a phase 1, dose-escalating, randomised controlled study, medRxiv (2021) 2021.05.03.21256309.","DOI":"10.1101\/2021.05.03.21256309"},{"issue":"13","key":"10.1016\/j.jpba.2021.114356_bib16","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1021\/ac020361s","article-title":"Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS\/MS","volume":"75","author":"Matuszewski","year":"2003","journal-title":"Anal. Chem."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708521004672?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708521004672?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:14:09Z","timestamp":1760001249000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708521004672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":16,"alternative-id":["S0731708521004672"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2021.114356","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The development and validation of a novel LC-MS\/MS method for the simultaneous quantification of Molnupiravir and its metabolite \u00df-d-N4-hydroxycytidine in human plasma and saliva","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2021.114356","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114356"}}